Combination Therapy Potential of HTD1801 (Berbe-rine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease
Abstract
Background: : Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are central to the cardiovascular-kidney-metabolic (CKM) continuum, where metabolic injury, hepatocellular stress, and systemic inflammation converge. These features represent key markers across the MASLD and CKM continuum. In this context, HTD1801, an ionic complex of berberine and ursodeoxycholic acid (UDCA), has shown improvements in glycemic control, LDL cholesterol, hepatic fat, and liver enzymes in clinical trials. The evidence base remains limited, with trials conducted in China and the United States and no biopsy-confirmed histologic outcomes yet reported. Main body: This review summarizes the mechanistic profile of HTD1801 and examines potential intersections with therapies commonly used in MASLD/MASH and CKM disease. Metformin is currently the only partner supported by Phase 3 randomized data demonstrating efficacy of HTD1801 as add-on therapy. For GLP-1 receptor agonists, statins, and SGLT2 inhibitors, combination rationale is biologically plausible but rests on mechanistic, preclinical, or comparative evidence rather than randomized human combination trials. Combinations with PPAR agonists or resmetirom remain hypothetical pending direct combination data and published biopsy-based efficacy results for HTD1801.
Conclusions:: HTD1801 occupies an intermediate position between metabolic and liver-directed therapy. Its role is promising but not yet fully defined.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.